Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

LadRx Corp LADX

Healthcare Biotechnology
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.


OTCQB:LADX - Post by User

LadRx Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by MissionIRon Feb 03, 2014 6:56pm
312 Views
Post# 22167766

CytRx Corp. (CYTR) Presenting at the 16th Annual BIO CEO & I

CytRx Corp. (CYTR) Presenting at the 16th Annual BIO CEO & I

CytRx Corp. (CYTR) Presenting at the 16th Annual BIO CEO & Investor Conference

CytRx today released a news release stating it will be presenting at the 16th Annual BIO CEO & Investor Conference next week at the Waldorf Astoria in New York City. CytRx’s President and CEO, Steven A. Kriegsman, as well as Vice President of Business Development, David Haen, will be presenting a corporate update on Monday, February 10, 2014 at 2:30 pm EST (11:30 am PST).

Among other things, the company will be covering its expanded 2014 aldoxorubicin development pipeline after its recent successful $75 million financing. Onlookers are advised to visit the company’s Investors section, at: www.cytrx.com/investors/presentations.

CytRx is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin.

For more information, visit: www.cytrx.com

Please read full disclaimers at https://disclaimer.missionir.com


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities